Author： Singh Steven
Publisher： Springer Publishing Company
ISSN： 1383-875X
Source： Journal of Interventional Cardiac Electrophysiology, Vol.10, Iss.1, 2004-02, pp. : 71-76
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Despite the recent results of the AFFIRM trail showing that either strategy of rate control or rhythm control is acceptable, there is general agreement that therapy must be individualized. Antiarrhythmic drugs while being effective in maintaining sinus rhythm are not without side effects. Thus, there continues to be a search for safer and better tolerated agents.Azimilide is a novel class 3 agent that blocks both components of the delayed rectifier current, while dofetilide blocks only the slow component. Dronedarone is somewhat similar to aminodarone, but perhaps with the side effects. Tedisamil is a complex class 3 agent, blocking multiple channels. Piboserod is a selective 5-HT receptor antagonist that is being investigated in clinical trials.
Related content
Access to resources
Recommend
By Wettwer Erich Christ Torsten Endig Sebastian Rozmaritsa Nadiia Matschke Klaus Lynch Joseph J. Pourrier Marc Gibson John K. Fedida David Knaut Michael Ravens Ursula
Cardiovascular Research, Vol. 98, Iss. 1, 2013-04 ,pp. :
Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology, Vol. 5, Iss. 3, 2007-07 ,pp. :